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Abstract
Recently, we reported a SOMAmer-based, highly multiplexed assay for the purpose of biomarker identification. To enable
seamless transition from highly multiplexed biomarker discovery assays to a format suitable and convenient for diagnostic
and life-science applications, we developed a streamlined, plate-based version of the assay. The plate-based version of the
assay is robust, sensitive (sub-picomolar), rapid, can be highly multiplexed (upwards of 60 analytes), and fully automated.
We demonstrate that quantification by microarray-based hybridization, Luminex bead-based methods, and qPCR are each
compatible with our platform, further expanding the breadth of proteomic applications for a wide user community.
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Introduction
Anticipation of the utility of analysis of large-scale proteomic
content dates back to the realization that phenotypes are
manifested by proteins. Successful proteomic analyses, using 2-D
gels, were carried out as early as the 1970’s [1], and since, interest,
technologies, and expectations have continued to develop and
escalate. Currently, applications envisioned for proteomic analysis
span numerous arenas, including biomarker discovery, life science
research, pharmaceutical research, and medical diagnostics. The
considerable promise of proteomic measurements in these areas is
now being realized, although limitations of current proteomic
technologies have impeded development of the more ambitious
applications thus far envisioned.
Current proteomic measurement methods tend be limited with
respect to throughput, sensitivity, or multiplicity [2]. We
previously developed a proteomic platform that promises to
surpass current technologies with respect to these limitations. The
assay is highly multiplexed, sensitive (sub-picomolar), reproduc-
ible, and quantitative [3]. It is based on affinity capture, and
therefore has some parallels with antibody-based methods. The
assay utilizes synthetic DNA SOMAmers (Slow Off-rate Modified
Aptamers) as protein capture reagents rather than antibodies.
SOMAmers are short, single stranded deoxyoligonucleotides.
Like aptamers, they are selected in vitro from large random libraries
for their ability to bind to discrete molecular targets, which can be
small molecules, peptides, or proteins [4,5]. SOMAmers are unlike
aptamers in that they bear dU residues that are uniformly
functionalized at the 5-position with moieties (e.g. benzyl,
2-napthyl, or 3-indolyl-carboxamide) that can participate in
interactions with target molecules as well as form novel secondary
and tertiary structural motifs within the SOMAmer itself ([6] data
not shown). Nuclease resistance and selection success rates [3] are
greatly improved over aptamers, and affinities are comparable to
antibodies.
Hence, SOMAmers bear significant promise as synthetic
protein-binding reagents [5,6,7]. In particular, we find that
problems of capture reagent cross-reactivity and non-specific
adsorption to surfaces are diminished or absent in our SOMAmer-
based protein measurement assays. These are issues that limit the
intrinsic multiplexing capability of antibody-based proteomic
assays to 30–50 analytes [2]. In contrast, at the time of this
writing, our SOMAmer-based, high-content biomarker discovery
platform reliably measures more than one thousand protein
analytes in a single sample ([3] data not shown). As yet, we do not
anticipate an upper limit to the multiplex capacity of this platform.
Here we present a streamlined, microtiter plate-based version of
our multiplex SOMAmer-based proteomics discovery assay. The
assay is intended to provide a rapid, efficient and seamless transition
from SOMAmer-based protein biomarker panel identification
[3,10,11] to routine proteomic measurements. Potential applica-
tions include in vitro diagnostic assays, assays intended to facilitate
clinical drug development, and indeed, any proteomic measure-
ment that might otherwise be carried out by ELISA.
At the core of our SOMAmer-based protein measurement
assays is an analyte capture reagent that consists of a fully synthetic
SOMAmer coupled to a biotin moiety through a photocleavable
linker (referred to as a ‘‘PB-SOMAmer’’, Figure 1A). The biotin
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26332Figure 1. SOMAmer-based assay reagent and assay principles. The primary analyte capture reagent and quantified component consists of an
analyte-specific SOMAmer coupled to a Cy3 moiety and a biotin group joined to the fluorophore-substituted SOMAmer through a photocleavable
linker (Panel A). The principal features of the assay consist of equilibration of capture reagent and analyte mixture in solution, followed by
immobilization of the entire capture reagent population on immobilized streptavidin through the biotin moieties of the capture reagent population.
The immobilized capture reagent population, including analyte/capture reagent complexes, is washed to remove non-complexed proteins.
Immobilized protein analytes are then biotinylated using a conventional amine-reactive biotinylation reagent. The entire capture reagent population,
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immobilization and wash steps, while the photocleavable linker
permits release of the SOMAmer into solution after washing. A
Cy3 fluorophore built into the capture reagents used in this study
permits quantification by means of commercially available slide-
based microarray hybridization systems, but is not required for all
formats of the assay.
The assays themselves consist of a binding step in which PB-
SOMAmers and analytes are equilibrated in solution (Figure 1B
Panel 1), followed by immobilization of all PB-SOMAmers on a
streptavidin-substituted support (Figure 1B Panel 2, ‘‘Catch-1’’).
Subsequent washes remove proteins that are not stably complexed
with PB-SOMAmers. Proteins immobilized through interaction with
bound PB-SOMAmers are biotinylated with an amine-reactive
biotinylation reagent (N-hydroxysuccinimide-PEO4-biotin). After
further washes, the entire SOMAmer population, including ana-
lyte-SOMAmer complexes, is released into solution via long-wave
ultraviolet light-catalyzed cleavage of the biotin-bearing photoclea-
vable linker (Figure 1B Panel 3). The biotinylated analyte-SOMAmer
complexes are then selectively captured on another streptavidin
support (Figure 1B Panel 4, ‘‘Catch-2’’) and the remaining, non-
complexed SOMAmers are washed away. Finally, analyte-bound
SOMAmers are eluted by disrupting the affinity interaction
(Figure 1B Panel 5). Eluted SOMAmers are surrogates for analyte
concentrations that can be quantified by standard DNA-quantifica-
tion methods, for example, qPCR, or hybridization to microarrays
(Figure 1B Panel 6).Conversion of arbitrary DNA measurement units
that reflect protein concentrations into actual protein concentration
units is accomplished through use of standard curves.
Results
To develop the plate-based SOMAPanel assay, a model
multiplex consisting of nine PB-SOMAmers specific for the
proteins IL-8, tPA, resistin, MIP-4, MMP-7, MMP-9, RANTES,
MCP-1, and Lipocalin 2, and twenty control PB-SOMAmers, was
assembled. These target analytes were chosen arbitrarily from our
complete SOMAmer menu as representative of three broad ranges
of abundance in plasma or serum, and because their PB-
SOMAmer capture reagents had been rigorously demonstrated
as specific for their respective analytes by pull-down assay
(Supporting Figure S1). The twenty control PB-SOMAmers
consist of a mixture of sequences designed to have particular
secondary structure motifs found in bona fide SOMAmers (for
example, stem-loop or G-quartet) and sequences selected to
recognize non-human proteins (for example, Green Fluorescent
Protein (GFP) from Aequorea victoria, a ´-hemolysin from Staphylococcus
aureus, firefly luciferase, keyhole limpet cyanin, and glutaredoxin
from Escherichia coli. These were used to monitor non-specific
plasma-dependent SOMAmer signaling in the course of assay
development (data not shown). This SOMAmer panel will be
referred to as a ‘‘nine-plex’’ although it consists of nine capture
reagents proper plus additional controls.
Features of the plate-based SOMAPanel assay
Substitution of streptavidin plates for streptavidin-agarose beads
and magnetic streptavidin beads eliminates both vacuum filtration
and magnetic separation from the assay protocol. In manual form,
the assay becomes a ‘‘wash and dump’’ procedure that is
reminiscent of an ELISA-based assay. The hands-on processing
time, which excludes equilibration and the initial streptavidin
capture (3.5 hours), is roughly 70 minutes. A diagram of the assay
steps is shown in Figure 2A. It should be noted that equilibration
time is a flexible parameter dictated by analyte abundance and
requirements for sensitivity. We have chosen a long equilibration
time here to maximize sensitivity for extremely sparse analytes.
Very acceptable results have been obtained with equilibration
times as short as 15 minutes (data not shown).
Dose-response curves with purified analytes generated in the
plate-based assay performed manually are shown in Figure 2B.
This 9-plex measurement compared assay response to increasing
spiked-in analyte concentration as a function of PB-SOMAmer
concentration in the presence of plasma. The dynamic range of
the assay is, for analytes shown, roughly 3 logs. In general, little
sensitivity or dynamic range is gained by elevated SOMAmer
concentrations. We have chosen an intermediate concentration,
0.5 nM for each PB-SOMAmer, for the work shown here, though
it is apparent from the curves that more or less PB-SOMAmer can
be used in this particular analyte panel without significant penalty.
Semi-automation of the plate-based assay
It was anticipated that the ‘‘wash and dump’’ nature of the
plate-based assay would permit automation using commercially
available, relatively low-cost instrumentation intended for ELISA.
The nature of the assay suggested that the additional capability of
multiple reagent addition would permit near-complete automa-
tion. The commercially available BioTek EL406 was selected for
this capacity. In addition to its conventional plate-washing
capability, the EL406 supports addition of up to six different
reagents, which is the number of solutions used in this assay.
We adapted the manual protocol for use with the EL406. The
resulting semi-automated, plate-based assay protocol proved
considerably more rapid and convenient than the semi-automated
bead-based assay. The post-equilibration processing time was
reduced from one hundred fifty minutes to fifty minutes. Hands-on
operations for the semi-automated assay became limited to
movement of plates from plate washer to UV lamp and back
and transfer of samples from one plate to another after
photocleavage.
To assess assay performance, we generated precision profiles for
each analyte in this assay format, and compared these with
precision profiles generated in our biomarker discovery assay
format. Precision profiles provide a quantitative measure of assay
performance. In a precision profile, the coefficient of variation
(%CV, determined from 8 replicates of each data point in this
case) is plotted as a function of analyte concentration. Upper and
lower limits of quantification (ULOQ and LLOQ, respectively),
defined in this case as analyte concentrations at which %CV’s
exceed 20% may be established from these plots. Quantification
range is defined as the range of analyte concentrations for which
the %CV is less than 20%.
Comparison of ULOQ’s, LLOQ’s, and quantification ranges
measured in the 9-plex, semi-automated, plate-based assay format
with those measured in the bead-based biomarker discovery assay
including biotinylated analyte/capture reagent complexes, is then released into solution via photocleavage. Biotinylated analyte/capture reagent
complexes are exclusively captured on immobilized streptavidin via the biotin moieties appended to the analyte population. Washes remove the
capture reagent population at large, leaving only analyte/capture reagent complexes. The remaining capture reagent population is a surrogate for
the analyte/capture reagent population. This material is eluted from immobilized analytes and quantified via conventional DNA quantification
methods.
doi:10.1371/journal.pone.0026332.g001
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(Figure 3 and Supporting Figure S2, compare left and right
panels). We conclude that assay performance of the two assay
formats is similar.
A summary comparison of the properties of the two assays is
presented in Table 1.
Nucleic acid quantification schemes
The bead-based biomarker discovery assay and plate-based
experiments shown up to this point use a nucleic acid
quantification system based on hybridization to printed micro-
arrays from Agilent to quantify SOMAmers in the final assay
eluate. This system currently has the capacity to quantitatively
measure more than 3000 analytes per sample, and even higher
levels of multiplexing are anticipated. It has proven sensitive and
convenient for very highly multiplexed biomarker discovery
applications. However, many labs have invested in other
potentially suitable hybridization-based nucleic acid quantification
instrumentation. Hence, we compared an alternative bead-based
nucleic acid quantification platform with Agilent microarrays with
respect to compatibility with our SOMAmer-based multiplex
assay.
We generated precision profiles and determined limits of
quantification of 9 analytes in multiplex format, in exactly the
same manner as in Figure 3. We split the final eluates into two
parts and independently determined limits of quantification using
Agilent microarrays and the Luminex bead-based system as a final
readout (Table 2). We found that sensitivity and dynamic ranges
are roughly comparable between the two platforms, although
Luminex was slightly less sensitive than Agilent (Table 2, compare
columns 2 and 3), and exhibited slightly elevated upper limits of
quantification (Table 2, compare columns 4 and 5).
Our biomarker discovery efforts have revealed that analyte
concentration differences that distinguish case from control
populations are often subtle. Indeed, we have discovered useful
biomarkers that differ by as little as twenty percent between case
and control [9]. To determine whether the plate-based assay in
combination with a Luminex bead-based nucleic acid readout is
suitable for measurements involving such subtle analyte concen-
tration differences in the region of endogenous levels, we spiked in
analytes in 20% increments, in quintuplicate, in the regions of
analyte signal previously measured in serum titrations (Supporting
Figure S4). It should be noted that listed analyte concentrations
are nominal, based on protein mass as noted by the manufacturer
Figure 2. Diagram of manual plate-based assay steps and dose-response curves generated in manual plate-based assay format. The
five steps of the manual plate-based assay - equilibration, biotinylation, photocleavage, and elution, are punctuated by three wash-and-dump cycles
and one liquid transfer. The total processing time is about 70 minutes (Panel A). A set of dose response curve generated in a nine-plex manual assay
format at various capture reagent concentrations (Panel B). Dose-response curves were generated by spiking analytes into plasma at the indicated
concentrations. Shown are resistin and MCP-1. Dose-response curves of MIP-4, RANTES, MMP-9, MMP-7, Lipocalin 2, tPA, and IL-8 can be found in
Supporting Materials.
doi:10.1371/journal.pone.0026332.g002
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to infer actual endogenous concentrations.
We find that even at these low levels of signal, subtle changes in
concentration can be measured with good precision (Figure 4).
The average CV for all analytes was 6.1%, with linear responses in
the ranges tested.
Validating the plate-based front end with alternative
back-end readouts
We wished to determine whether the plate-based assay, in
combination with a bead-based nucleic acid (SOMAmer) readout,
is sufficiently sensitive and robust to separate case and control
populations within a clinical sample set. This is a commercial
diagnostic application anticipated for SOMAPanel assays. To this
end we performed an experiment in which various analytes were
spiked at levels comparable to those we have encountered in the
course of biomarker discovery into a collection of individual serum
samples, effectively creating a mock disease signature in a
population of samples. The ability to distinguish differential
expression of analytes, both up and down with respect to the
control population, forms a practical criterion for the adequacy of
the assay to discern target responses against the backdrop of
individual sample variance.
Serum samples from twenty-four healthy controls were used to
create a protein signature with both ‘‘up-’’ and ‘‘down-regulated’’
analytes. Two aliquots of each sample were used to produce a
separate control and a case population by adding analytes to each
group. Spikes into the twenty-four samples comprising the control
group will result in ‘‘down-regulated’’ measurements in the case
population while spikes into the case population will result in ‘‘up-
regulation’’. Spike concentrations were chosen to produce analyte
signals that differed by 1–2 standard deviations from the means of
the population distributions as determined from the twenty-four
individuals. These modest concentration differences were intended
to mimic real-world case and control samples, rather than simply
achieve clean separation of two populations. We spiked three
analytes into the control samples (tPA, MMP-9, and Lipocalin 2),
and four analytes in the case samples (IL-8, MCP-1, resistin and
RANTES). The model multiplex assay was used to explore
differential expression in this set of mock case and control samples.
The results are presented in Figure 5. Cumulative distribution
functions (CDFs) were constructed separately for the case and
control populations for each of the nine analytes. The three
analytes spiked into the control group result in clearly identified
‘‘down-regulation’’, while the four analytes spiked into the case
group appear as ‘‘up-regulation’’ in our mock protein signature.
The two analytes for which no spikes were added, MIP-4, and
MMP-7, display no differential expression, attesting to the
specificity of the SOMAmer assay. The magnitudes of the spiked
proteins were relatively small to result in mostly overlapping
distributions between case and control populations yet with
discernable differences that are comparable to those observed in
actual case/control proteomic studies [10]. The plate-based
SOMAmer assay performed well in this model multiplex
diagnostic application.
Finally, to verify that our results with spiked proteins can be
recapitulated with native analytes, we performed a reproducibility
study with the plate-based assay, using a Luminex read-out and
unspiked plasma samples. Eight identical pooled plasma samples
and plasma samples from 24 individuals were measured in 3
independent runs.
Intra- and inter-run coefficients of variation (CV’s) within the 8
pooled plasma samples were calculated. The median intra-run CV
was 11.4%, while the median inter-run CV was 11.9% (Table 3).
These values are well within our hypothetical case/control
variation of 20%.
Spearman’s rank correlation coefficients (Spearman’s Rho’s)
were calculated for each analyte within the 24 individuals between
runs 1 and 2, 1 and 3, and 2 and 3 (Table 3). Spearman’s Rho’s
provide a metric for reproducibility of subtle individual variations,
and ultimately, a surrogate measurement for ability to distinguish
case from control in test populations. It should be noted that in the
Figure 3. Precision profiles and limits of quantification of plate- and bead-based assays. Eight individual measurements of fluorescent
signal as a function of analyte concentration in buffer were made for each of nine analytes in multiplexed format. For the dose-response curves (left
of each panel), the average RFU at each concentration is denoted by the blue markers and the eight individual measurements used to compute each
average are denoted by the red markers plotted on the four parameter curve fit (solid blue line). Precision profiles (right of each panel) were
computed with two different methods: (1) by calculating the variance in computed concentrations (blue, bottom left of each panel) and (2) by
calculating the variance in log RFU (assay response, top right of each panel) combined with the slope of the standard curve (red). Limits of
quantification were defined as points on the curves where the coefficient of variation (CV) exceeded 20%. Panels A, C, and E were generated in plate-
based format. Panels B, D, and F were generated in bead-based format. Analytes measured were MCP-1 (Panels A and B), MMP9 (Panel C and D),
resistin (Panels E and F) tPA (Figure S1B), MMP-7 (Figure S2B), IL-8 (Figure S2A), Lipocalin 2 (Figure S2A), MIP-4 (Figure S2A), Protein S (Figure S2B) and
RANTES (Figure S2B).
doi:10.1371/journal.pone.0026332.g003
Table 1. Comparison of automated bead-based Discovery-plex and plate-based SOMAPanel assay formats.
Metric Bead-based Discovery Assay Plate-based SOMAPanel Targeted Assay
Partitioning Method (Capacity) Catch 1 – SA Agarose Beads (.1000-plex) Catch 1 & 2 – SA plates (,200-plex)
Up-front Prep (Time) Bead prep (,30 minutes) Robotic setup None
Post-equilibration processing time ,150 minutes ,50 minutes
Throughput 96 samples/day/FTE 384 samples/day/FTE
Manual operation Yes Yes
Average LLOQ ,1p M ,2p M
Coefficient of variation ,5% ,7%
Automation instrumentation Biomek FX with modifications Stock BioTek EL406 plate washer
doi:10.1371/journal.pone.0026332.t001
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Spearman’s correlations will break down, and thus Spearman’s
correlations within a normal population can represent an
artificially high bar for ability to distinguish test and control.
Conversely, wide population distributions can generate very high
Spearman’s correlations. Here, we present Spearman’s correla-
tions as a simple demonstration that our assay can reproducibly
distinguish subtle variations in analyte signal in native, unspiked
plasma samples.
Discussion
We developed a streamlined multiplexed SOMAmer-based
assay that is robust, sensitive, and quantitative. It is designed to
enable the translation of discovery biomarker panels into robust
diagnostic products and to facilitate use of small panels during
clinical development of drugs. The ease of use of the assay is
roughly comparable to that of single-analyte ELISA. The assay is
easily and inexpensively automated. Throughput can be made
relatively high and sample volumes are quite small (,15 mL).
Equipment and materials for the assay are commercially available
from several sources. The final readout can be made inexpensive
and scaled according to analyte number by use of a commercially
available, bead-based nucleic acid quantification system.
Recently, we have identified several biomarker panels with
potential diagnostic applications for chronic kidney disease [3],
lung cancer [10], mesothelioma, and pancreatic cancer [in
preparation]. Use of these biomarker panels in diagnostic
applications will require the measurement of perhaps 9–15
analytes in a single sample. The streamlined assay presented here
permits seamless transition from such biomarker panels identified
in SOMAScan-based studies to actual diagnostic applications. We
have demonstrated such utility by spiking analytes into a sample
population to produce typical differential expression observed in
proteomic studies of case/control groups. We have further
demonstrated that even the subtle variations in native analyte
levels within a normal population can be reproducibly distin-
guished.
We have found that the bead-based nucleic acid quantification
system from Luminex can be used for final readout without
significant performance penalty. This is advantageous in that it
permits scaling of the final readout to the number of analytes to be
measured. As such, the assay can be made more economical for
applications involving specific small analyte panels. Moreover, the
demonstration that several readout platforms may be used will
render the SOMAmer-based assay easily accessible to groups and
institutions that already possess other gene expression measure-
ment platforms.
We have also explored the use of real-time quantitative PCR
(qPCR) as a back-end read-out for the plate- and bead-based
assays. As might be expected, qPCR is exquisitely sensitive, and
can be made reproducible and quantitative with appropriate
optimization (Figure S3 and data not shown). We conclude that
qPCR is a viable back-end readout option for the SOMAmer-
based assay presented here, as is any other nucleic acid
quantification scheme. It is certainly suitable for experimentation
as well as routine assays in labs that possess the necessary
equipment.
We have only briefly explored the upper limits of multiplex
capacity of the plate-based assay but have verified that at least 60
analytes, selected from a lung cancer panel identified as
biomarkers in an 836-plex SOMAScan assay, may be multiplexed
without optimization (Figure S5).
The use of SOMAmers as capture reagents carries advantages
over traditional antibody-based immunoassays. The synthetic
nature of SOMAmers ensures uniformity and availability.
Customization of the affinity reagent is routine, relying only on
the availability of the appropriate phosphoramidites. SOMAmers
are as chemically stable as DNA and resistant to at least 10 freeze-
thaw cycles when buffered (Steve Wolk, pers. comm.). Heat
denaturation of SOMAmers is completely reversible and in fact
SOMAmers are routinely heated to 95 C prior to use (see
Materials and Methods). Custom generation of SOMAmers to
protein targets is generally rapid and inexpensive compared to
antibodies. The intrinsic limitations of multiplex capabilities of
antibodies are greatly diminished with SOMAmers. To date, we
have successfully multiplexed up to 1034 SOMAmer measure-
ments in a single 15 mL sample and do not anticipate an upper
limit on multiplexing.
Materials and Methods
Purchased reagents
HEPES, NaCl, KCl, EDTA, EGTA, MgCl2 and Tween-20
were purchased from Fisher Biosciences. Dextran sulfate sodium
salt (DxSO4), nominally 8000 molecular weight, was purchased
from AIC and dialyzed against deionized water for at least
20 hours with one exchange. KOD EX DNA polymerase was
purchased from VWR. Tetramethylammonium chloride and
CAPSO were purchased from Sigma-Aldrich and streptavidin-
Table 2. Comparison of slide-based and bead-based read-out formats.
Lower Limit of Quantification (pM) Upper Limit of Quantification (pM) Quantification Range (logs)
Analyte Agilent Luminex Agilent Luminex Agilent Luminex
IL-8 0.32 0.5 210 240 2.8 2.7
MIP-4 0.66 2.0 3,600 1000,000 3.8 5.7
Lipocalin-2 0.83 0.78 260 1,500 2.5 3.3
MCP-1 1.2 1.8 700 1,500 2.8 3.9
RANTES 1.8 3.5 420 360 2.4 2.0
MMP-7 1.9 6.8 550 1,100 2.5 2.2
resistin 1.4 1.8 1,900 4,400 3.1 3.4
MMP-9 1.6 5.4 13,000 19,000 3.9 3.5
tPA 1.2 3.2 1,300 1,400 3.1 2.7
doi:10.1371/journal.pone.0026332.t002
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PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e26332Figure 4. High-resolution titration of analytes. Analytes were titrated in 20% concentration increments in the region of signal generated by
serum without spikes. Assay eluates were quantified by Luminex bead hybridization.
doi:10.1371/journal.pone.0026332.g004
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PLoS ONE | www.plosone.org 8 October 2011 | Volume 6 | Issue 10 | e26332Figure 5. Differential expression between case and control populations. Twenty-four case samples and twenty-four control samples were
measured using the model 9-plex plate-based assay. Empirical CDFs were constructed for the control (blue) and case (red) populations separately for
each analyte and are displayed in panels a–i. Spikes into the control samples (tPA, MMP-9, and Lipocalin 2) result in clear ‘‘down-regulation’’, spikes
into case samples (IL-8, MCP-1, resistin and RANTES) result in clear ‘‘up-regulation’’ and the two analytes not spiked (MIP-4 and MMP-7) show no
differential expression.
doi:10.1371/journal.pone.0026332.g005
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Aminoethyl)-benzenesulfonylfluoride hydrochloride (AEBSF) was
purchased from Gold Biotechnology. Streptavidin-coated 96-well
plates were purchased from Thermo Scientific (Pierce Streptavidin
Coated Plates HBC, clear, 96-well, product number 15500 or
15501). NHS-PEO4-biotin was purchased from Thermo Scientific
(EZ-Link NHS-PEO4-Biotin, product number 21329), dissolved in
anhydrous DMSO, and stored frozen in single-use aliquots. IL-8,
MIP-4, Lipocalin-2, RANTES, MMP-7, and MMP-9 were
purchased from R&D Systems. Resistin and MCP-1 were
purchased from PeproTech, and tPA was purchased from VWR.
Nucleic acids
Conventional (including amine- and biotin-substituted) oligo-
deoxynucleotides were purchased from Integrated DNA Technol-
ogies (IDT). Z-Block is a single-stranded oligodeoxynucleotide of
sequence 59- (AC-BnBn)7-AC-39, where Bn indicates a benzyl-
substituted deoxyuridine residue. Z-block was synthesized in-
house, using conventional phosphoramidite chemistry. SOMAmer
capture reagents were synthesized in-house by conventional
phosphoramidite chemistry, and purified on a 21.5675 mm
PRP-3 column, operating at 80uC on a Waters Autopurification
2767 system (or Waters 600 series semi-automated system), using a
timberline TL-600 or TL-150 heater and a gradient of
triethylammonium bicarbonate (TEAB) / ACN to elute product.
Detection was performed at 260 nm and fractions were collected
across the main peak prior to pooling best fractions.
Buffers
Buffer SB18 is composed of 40 mM HEPES, 101 mM NaCl,
5 mM KCl, 5 mM MgCl2, and 0.05% (v/v) Tween 20 adjusted to
pH 7.5 with NaOH. Buffer SB17 is SB18 supplemented with
1 mM trisodium EDTA. Buffer PB1 is composed of 10 mM
HEPES, 101 mM NaCl, 5 mM KCl, 5 mM MgCl2,1 m M
trisodium EDTA and 0.05% (v/v) Tween-20 adjusted to pH 7.5
with NaOH. CAPSO elution buffer consists of 100 mM CAPSO
pH 10.0 and 1 M NaCl. Neutralization buffer consists of 500 mM
HEPES, 500 mM HCl, and 0.05% (v/v) Tween-20. Agilent
Hybridization Buffer is a proprietary formulation that is supplied
as part of a kit (Oligo aCGH/ChIP-on-chip Hybridization Kit).
Agilent Wash Buffer 1 is a proprietary formulation (Oligo aCGH/
ChIP-on-chip Wash Buffer 1, Agilent). Agilent Wash Buffer 2 is a
proprietary formulation (Oligo aCGH/ChIP-on-chip Wash Buffer
2, Agilent). TMAC hybridization solution consists of 4.5 M
tetramethylammonium chloride, 6 mM trisodium EDTA,
75 mM Tris-HCl (pH 8.0), and 0.15% (v/v) Sarkosyl. KOD
buffer (10-fold concentrated) consists of 1200 mM Tris-HCl,
15 mM MgSO4, 100 mM KCl, 60 mM (NH4)2SO4, 1% v/v
Triton-X 100 and 1 mg/mL BSA.
Sample preparation
Serum (stored at 280uC in 100 mL aliquots), was thawed in a
25uC water bath for 10 minutes, then stored on ice prior to sample
dilution. Samples were mixed by gentle vortexing for 8 seconds. A
6% serum sample solution was prepared by dilution into 0.946
SB17 supplemented with 0.6 mM MgCl2, 1 mM trisodium
EGTA, 0.8 mM AEBSF, and 2 mM Z-Block. A portion of the
6% serum stock solution was diluted 10-fold in SB17 to create a
0.6% serum stock. 6% and 0.6% stocks are used to detect high-
and low-abundance analytes, respectively.
Capture reagent (SOMAmer) and streptavidin plate
preparation
SOMAmers were grouped into 2 mixes according to the relative
abundance of their cognate analytes. SOMAmers consigned to the
low-abundance group were those that recognize IL-8, MMP-7,
resistin, and tPA. SOMAmers consigned to the high-abundance
group were those that recognize Lipocalin-2, MCP-1, MIP-4
(PARC), MMP-9, and RANTES. Stock concentrations were 4 nM
in each SOMAmer, and the final concentration of each
SOMAmer was 0.5 nM. SOMAmer stock mixes were diluted 4-
fold in SB17 buffer, heated to 95uC for 5 min and cooled to 37uC
over a 15 minute period prior to use. This denaturation-
renaturation cycle is intended to normalize SOMAmer conformer
distributions and thus ensure reproducible SOMAmer activity in
spite of variable histories. Streptavidin plates were washed twice
with 150 mL buffer PB1 prior to use.
Equilibration and plate capture
Heat-cooled 26SOMAmer mixes (55 mL) were combined with
an equal volume of 6% or 0.6% serum dilutions, producing
equilibration mixes containing 3% and 0.3% serum. The plates
were sealed with a Silicone Sealing Mat (Axymat Silicone sealing
mat, VWR) and incubated for 1.5 h at 37uC. Equilibration mixes
were then transferred to the wells of a washed 96-well streptavidin
plate and further incubated on an Eppendorf Thermomixer set at
37uC, with shaking at 800 rpm, for two hours.
Manual Assay
Unless otherwise specified, liquid was removed by dumping,
followed by two taps onto layered paper towels. Wash volumes
were 150 mL and all shaking incubations were done on an
Table 3. Reproducibility study using Luminex readout.
Analyte
Mean RFU (std dev)
(8 calibrators, 3 runs)
Inter-run CV (%) (8
calibrators, 3 runs)
Intra-run CV (%)
(8 calibrators)
Median Spearman’s
Rho (24 individuals) P-value
IL-8 104 (12) 11.6 11.8 0.471 2.0610
22
MIP-4 808 (87) 10.9 9.6 0.875 2.3610
28
Lipocalin-2 609 (105) 17.3 12.4 0.495 1.4610
22
MCP-1 203 (16.3) 8.1 8.2 0.617 1.3610
23
RANTES 409 (47) 11.4 10.3 0.795 3.5610
26
MMP-7 193 (19.8) 10.3 11.9 0.590 2.4610
23
resistin 153 (20) 11.6 11.8 0.449 2.8610
22
MMP-9 168 (17.2) 10.3 8.4 0.829 5.7610
27
doi:10.1371/journal.pone.0026332.t003
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mixes were removed by pipetting, and plates washed twice for
1 minute with buffer PB1 supplemented with 1 mM dextran
sulfate and 500 mM biotin, then 4 times for 15 seconds with buffer
PB1. A freshly made solution of 1 mM NHS-PEO4-biotin in
buffer PB1 (150 mL/well) was added, and plates incubated for
5 minutes with shaking. The NHS-biotin solution was removed,
and plates washed 3 times with buffer PB1 supplemented with
20 mM glycine, and 3 times with buffer PB1. Eighty-five mLo f
buffer PB1 supplemented with 1 mM DxSO4 were then added to
each well, and plates were irradiated under a BlackRay UV lamp
(nominal wavelength 365 nm) at a distance of 5 cm for 20 minutes
with shaking. Samples were transferred to a fresh, washed
streptavidin-coated plate, or an unused well of the existing washed
streptavidin plate, combining high and low sample dilution
mixtures into a single well. Samples were incubated at room
temperature with shaking for 10 minutes. Unadsorbed material
was removed and the plates washed 8 times for 15 seconds each
with buffer PB1 supplemented with 30% glycerol. Plates were then
washed once with buffer PB1. SOMAmers were eluted for
5 minutes at room temperature with 100 mL CAPSO elution
buffer. 90 mL of the eluate was transferred to a 96-well HybAid
plate and 10 mL neutralization buffer was added.
Semi-Automated Assay
Streptavidin plates bearing adsorbed equilibration mixes were
placed on the deck of a BioTek EL406 plate washer, which had
been programmed to perform the following steps: unadsorbed
material is removed by aspiration, and wells are washed 4 times
with 300 mL of buffer PB1 supplemented with 1 mM dextran
sulfate and 500 mM biotin. Wells are then washed 3 times with
300 mL buffer PB1. One hundred fifty mL of a freshly prepared
(from a 100 mM stock in DMSO) solution of 1 mM NHS-PEO4-
biotin in buffer PB1 is added. Plates are incubated for 5 minutes
with shaking. Liquid is aspirated, and wells were washed 8 times
with 300 mL buffer PB1 supplemented with 10 mM glycine. One
hundred mL of buffer PB1 supplemented with 1 mM dextran
sulfate are added. After these automated steps, plates were
removed from the plate washer and placed on a thermoshaker
mounted under a UV light source (BlackRay, nominal wavelength
365 nm) at a distance of 5 cm for 20 minutes. The thermoshaker
was set at 800 rpm and 25uC. After 20 minutes irradiation,
samples were manually transferred to a fresh, washed streptavidin
plate (or to an unused well of the existing washed plate). High-
abundance (3% serum+3% SOMAmer mix) and low-abundance
reaction mixes (0.3% serum+0.3% SOMAmer mix) were com-
bined into a single well at this point. This ‘‘Catch-2’’ plate was
placed on the deck of BioTek EL406 plate washer, which had been
programmed to perform the following steps: the plate was
incubated for 10 minutes with shaking. Liquid is aspirated, and
wells are washed 21 times with 300 mL buffer PB1 supplemented
with 30% glycerol. Wells are washed 5 times with 300 mL buffer
PB1, and the final wash is aspirated. One hundred mL CAPSO
elution buffer are added, and SOMAmers are eluted for 5 minutes
with shaking. Following these automated steps, the plate was then
removed from the deck of the plate washer, and 90 mL aliquots of
the samples were transferred manually to the wells of a HybAid
96-well plate that contained 10 mL neutralization buffer.
Hybridization to custom Agilent 8615k microarrays
24 mL of the neutralized eluate were transferred to a new 96-
well plate and 6 mLo f1 0 6Agilent Block (Oligo aCGH/ChIP-on-
chip Hybridization Kit, Large Volume, Agilent 5188–5380),
containing a set of hybridization controls composed of 10 Cy3
SOMAmers was added to each well. Thirty mL2 6 Agilent
Hybridization buffer were added to each sample and mixed. Forty
mL of the resulting hybridization solution were manually pipetted
into each ‘‘well’’ of the hybridization gasket slide (Hybridization
Gasket Slide, 8-microarray per slide format, Agilent). Custom
Agilent microarray slides, bearing 10 probes per array comple-
mentary to 40 nucleotide random region of each SOMAmer with
a2 0 6dT linker, were placed onto the gasket slides according to
the manufacturers’ protocol. The assembly (Hybridization Cham-
ber Kit – SureHyb-enabled, Agilent) was clamped and incubated
for 19 hours at 60uC while rotating at 20 rpm.
Post Hybridization Washing
Approximately 400 mL Agilent Wash Buffer 1 was placed into
each of two separate glass staining dishes. Slides (no more than two
at a time) were disassembled and separated while submerged in
Wash Buffer 1, then transferred to a slide rack in a second staining
dish also containing Wash Buffer 1. Slides were incubated for an
additional 5 minutes in Wash Buffer 1 with stirring. Slides were
transferred to Wash Buffer 2 pre-equilibrated to 37uC and
incubated for 5 minutes with stirring. Slides were transferred to
a fourth staining dish containing acetonitrile, and incubated for
5 minutes with stirring.
Microarray Imaging
Microarray slides were imaged with an Agilent G2565CA
Microarray Scanner System, using the Cy3-channel at 5 mm
resolution at 100% PMT setting, and the XRD option enabled at
0.05. The resulting TIFF images were processed using Agilent
feature extraction software version 10.5.1.1 with the GE1_105_
Dec08 protocol. Primary Agilent data is available as Supplemen-
tary Information (Figure S6).
Luminex probe design
Probes immobilized to beads bore 40 deoxynucleotides
complementary to the 39 end of the 40 nucleotide random region
of the target SOMAmer. The SOMAmer complementary region
was coupled to Luminex Microspheres through a hexaethylene-
glycol (HEG) linker bearing a 59 amino terminus. Biotinylated
detection deoxyoligonucleotides consisted of 17–21 deoxynucleo-
tides complementary to the 59 primer region of target SOMAmers.
Biotin moieties were appended to the 39 ends of detection oligos.
Coupling of probes to Luminex Microspheres
Probes were coupled to Luminex Microplex Microspheres
essentially per the manufacturer’s instructions, but with the
following modifications: amino-terminal oligonucleotide amounts
were 0.08 nMol per 2.5610
6 microspheres, and the second EDC
addition was 5 mL at 10 mg/mL. Coupling reactions were
performed in an Eppendorf ThermoShaker set at 25uC and
600 rpm.
Microsphere hybridization
Microsphere stock solutions (about 40000 microspheres/mL)
were vortexed and sonicated in a Health Sonics ultrasonic cleaner
(Model: T1.9C) for 60 seconds to suspend the microspheres.
Suspended microspheres were diluted to 2000 microspheres per
reaction in 1.56 TMAC hybridization solutions and mixed by
vortexing and sonication. Thirty-three mL per reaction of the bead
mixture were transferred into a 96-well HybAid plate. Seven mLo f
15 nM biotinylated detection oligonucleotide stock in 16 TE
buffer were added to each reaction and mixed. Ten mLo f
neutralized assay sample were added and the plate was sealed with
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5 minutes and incubated at 50uC without agitation overnight in a
conventional hybridization oven. A filter plate (Dura pore,
Millipore part number MSBVN1250, 1.2 mm pore size) was
prewetted with 75 mL1 6 TMAC hybridization solution supple-
mented with 0.5% (w/v) BSA. The entire sample volume from the
hybridization reaction was transferred to the filter plate. The
hybridization plate was rinsed with 75 mL1 6TMAC hybridiza-
tion solution containing 0.5% BSA and any remaining material
was transferred to the filter plate. Samples were filtered under slow
vacuum, with 150 mL buffer requiring about 8 seconds to
evacuate. The filter plate was washed once with 75 mL1 6
TMAC hybridization solution containing 0.5% BSA and the
microspheres in the filter plate were resuspended in 75 mL1 6
TMAC hybridization solution containing 0.5% BSA. The filter
plate was protected from light and incubated on an Eppendorf
Thermalmixer R for 5 minutes at 1000 rpm. The filter plate was
then washed once with 75 mL1 6 TMAC hybridization solution
containing 0.5% BSA. 75 mLo f1 0mg/mL streptavidin phycoer-
ythrin (SAPE-100, MOSS, Inc.) in 16 TMAC hybridization
solution was added to each reaction and incubated on Eppendorf
Thermalmixer R at 25uC at 1000 rpm for 60 minutes. The filter
plate was washed twice with 75 mL1 6 TMAC hybridization
solution containing 0.5% BSA and the microspheres in the filter
plate were resuspended in 75 mL1 6 TMAC hybridization
solution containing 0.5% BSA. The filter plate was then incubated
protected from light on an Eppendorf Thermalmixer R for
5 minutes, 1000 rpm. The filter plate was then washed once with
75 mL1 6 TMAC hybridization solution containing 0.5% BSA.
Microspheres were resuspended in 75 mL1 6 TMAC hybridiza-
tion solution supplemented with 0.5% BSA, and analyzed on a
Luminex 100 instrument running XPonent 3.0 software. At least
100 microspheres were counted per bead type, under high PMT
calibration and a doublet discriminator setting of 7500 to 18000.
Primary Luminex readout data is available as a Supplementary
File (Hybridization Data).
QPCR read-out
Standard curves for qPCR were prepared in water ranging from
10
8 to 10
2 copies with 10-fold dilutions and a no-template control.
Neutralized assay samples were diluted 40-fold into diH2O. The
qPCR master mix was prepared at 26 final concentration (26
KOD buffer, 400 mM dNTP mix, 400 nM forward and reverse
primer mix, 26SYBR Green I and 0.5 U KOD EX). Ten mLo f
26qPCR master mix was added to 10 mL of diluted assay sample.
qPCR was run on a BioRad MyIQ iCycler with 2 minutes at 96uC
followed by 40 cycles of 96uC for 5 seconds and 72uC for
30 seconds.
Pull-down assay
Pull-down assays were performed as described previously
3.
Supporting Information
Figure S1 Demonstration of SOMAmer specificity by
pull-down assay. SOMAmers were incubated with target
proteins, plasma, or target proteins spiked into plasma for
45 minutes. Protein/SOMAmer complexes were captured on
magnetic streptavidin beads (MyOne C1), washed, and then
treated with a mixture of NHS-biotin and NHS-AlexaFluor 647.
Protein/SOMAmer complexes were photocleaved from beads and
a portion fractionated on SDS gels (first set of 3 lanes, marked
‘‘equilibrium’’). Protein/SOMAmer complexes were then ad-
sorbed to monomeric avidin agarose beads, washed, and then
eluted with 2 mM biotin in SB17. Complexes were captured a
third time onto magnetic streptavidin beads (MyOne C1)
substituted with a bound biotinylated-primer complementary to
the 39 fixed region of the SOMAmer. Not all SOMAmer
complexes can be captured onto these beads since the 39 fixed
regions of SOMAmers are sometimes inaccessible for annealing
while bound to the target protein (as evident in the gels for MMP-7
and MMP-9). The complexes were eluted by increasing the pH to
12, and then neutralized. Portions were fractionated on SDS gels
(second set of 3 lanes). Shown are purified target protein spiked
into buffer (lanes 1), purified target protein spiked into 10%
plasma (lanes 2), and 10% plasma with no spike (lanes 3).
(TIF)
Figure S2 Precision profiles and limits of quantification
of plate- and bead-based assays. Eight individual measure-
ments of fluorescent signal as a function of analyte concentration
in buffer were made for each of nine analytes in multiplexed
format. For the dose-response curves (left of each panel), the
average RFU at each concentration is denoted by the blue
markers and the eight individual measurements used to compute
each average are denoted by the red markers plotted on the four
parameter curve fit (solid blue line). Precision profiles (right of each
panel) were computed with two different methods: (1) by
calculating the variance in computed concentrations (blue, bottom
left of each panel) and (2) by calculating the variance in log RFU
(assay response, top right of each panel) combined with the slope of
the standard curve (red). Left-hand panels were generated in plate-
based (SOMAPanel) format. Right-hand panels were generated in
bead-based (SOMAscan) format. Limits of quantification were
defined as points on the curve in which the coefficient of variation
(CV) exceeded 20%.
(TIF)
Figure S3 QPCR readout of plate-based assay eluates.
Portions of samples generated in the experiment for Table 2 were
diluted and assayed by qPCR per Materials and Methods.
(TIF)
Figure S4 Serum titration. Serum was added at 0.078%,
0.156%, 0.313%, 0.625%, 1.25%, 2.50%, 5.00%, and 10.0% to
the 9-plex SOMAmer panel. The plate-based assay was performed
in semi-automated format and analyte signal measured as
described in Materials and Methods.
(TIF)
Figure S5 Minimum multiplex capacity of plate-based
assay platforms. Sixty-one SOMAmers recognizing analytes
identified as biomarkers on the bead-based SOMAScan platform
were combined. Serum was added at 0.011%, 0.035%, 0.11%,
0.35%, 1.1%, 3.45%, 10.9%, and 34.5% v/v, and analyte signal
measured as described in Materials and Methods. The log of the
ratio of analyte signal at 10.9% and 0.011% was calculated, and
plotted as a cumulative distribution function. Analyte signals at
10.9% serum are elevated at least 2.8-fold over those at 0.011%
serum for all sixty-one biomarkers.
(TIF)
Figure S6 Hybridization data. Raw data used to generate
Figures 2, 3, 4 and 5 is provided in spreadsheet format.
(XLSX)
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